Page last updated: 2024-08-24

triazoles and ritonavir

triazoles has been researched along with ritonavir in 38 studies

Research

Studies (38)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (10.53)29.6817
2010's31 (81.58)24.3611
2020's3 (7.89)2.80

Authors

AuthorsStudies
Burhenne, J; Ding, R; Drzewinska, M; Haefeli, WE; Mikus, G; Rengelshausen, J; Riedel, KD; Schöwel, V; Thomsen, T; Weiss, J1
Allison, MJ; Foster, G; Gandelman, K; Gutierrez, MJ; LaBadie, RR; Liu, P; Sharma, A1
Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H1
Krishna, G; Ma, L; Martinho, M; McLeod, J; Moton, A; Seiberling, M1
Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR1
Abel, S; Hui, J; Kearney, BP; Ramanathan, S; Tweedy, S; West, S1
D'Avolio, A; Fuchs, D; Gisslén, M; Hagberg, L; Svennerholm, B; Verhofstede, C; Watson, V; Yilmaz, A1
Giguère, P; Kravcik, S; la Porte, CJ; Toy, J1
Abel, S; Davis, J; Hamlin, J; Hoetelmans, RM; Kakuda, TN; Mack, R; Ndongo, N; Petit, W; Ridgway, C; Schöller-Gyüre, M; Sekar, V; Tweedy, S1
Burhenne, J; Haefeli, WE; Katzenmaier, S; Markert, C; Mikus, G; Riedel, KD1
Ainsworth, J; Cook, R; Dufty, N; Gandhi, K; Hickinbottom, G; Khonyongwa, K; Okoli, C; Owen, A; Siccardi, M; Taylor, S; Thomas-William, S; Watson, J1
Aouri, M; Buclin, T; Calmy, A; Decosterd, LA; Hirschel, B; Livio, F1
Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J1
Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C1
Dhiver, C; Durant, J; Gagnieu, MC; Garraffo, R; Katlama, C; Lê, MP; Muret, P; Peytavin, G; Poizot-Martin, I; Solas, C; Yeni, P1
Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M1
Back, D; Croucher, A; Else, LJ; Khoo, S; Mora-Peris, B; Scullard, G; Vera, JH; Winston, A1
Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Galli, A; Gonzalez de Requena, D; Lazzarin, A; Nozza, S; Simiele, M1
Baldelli, F; Cipriani, S; D'Amore, C; Fiorucci, S; Francisci, D; Mencarelli, A; Renga, B; Schiaroli, E1
Acosta, EP; Adeyemi, O; Berzins, B; Castro, J; Eron, JJ; Kuritzkes, DR; Lalezari, J; Lu, D; Ryscavage, P; Swindells, S; Taiwo, B; Tsibris, A1
Fang, A; Heera, J; Mendes da Costa, L; Plotka, A; Vourvahis, M1
Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK1
Bancalero, P; Chueca, N; García, C; Jiménez, P; Macías, J; Márquez, M; Merino, D; Muñoz, L; Ojeda, G; Pasquau, J; Pineda, JA; Recio, E1
Bonora, S; Calcagno, A; Chiappetta, S; D'Avolio, A; Di Perri, G; Ghisetti, V; Lazzarin, A; Milia, MG; Nozza, S; Simiele, M1
Achhra, AC; Boyd, MA; Cooper, DA; Kelleher, AD; Law, MG; Matthews, GV1
Bigoloni, A; Boeri, E; Castagna, A; Cavarelli, M; Galli, A; Mainetti, L; Nozza, S; Pignataro, AR; Sampaolo, M; Scarlatti, G; Tolazzi, M1
Antinori, A; Bonora, S; Chiappetta, S; De Battista, D; Di Pietro, M; Galli, L; Lazzarin, A; Malnati, M; Mazzotta, F; Nozza, S; Ottou, S; Pogliaghi, M; Ripa, M; Zaccarelli, M1
Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L1
Ahmed, N; Ainsworth, J; Okoli, C1
Amin, J; Andrade-Villanueva, J; Arnaiz, JA; Belloso, W; Clark, A; Clarke, A; Cooper, D; Emery, S; Fisher, M; Gatell, J; Gill, J; Harrigan, R; Horban, A; Kaiser, R; Kelleher, A; Losso, M; Mallon, P; Pett, SL; Porteiro, N; Prazuck, T; Rockstroh, JK; Ruxrungtham, K; Sierra Madero, J; Silk, D; Sugiura, W; Tu, E; Wolff, M; Woolley, I1
Arenas-Pinto, A; Benn, P; Brima, N; Clarke, A; Copas, A; Fisher, M; Gilson, R; Hawkins, D; Milinkovic, A; Schembri, G; Williams, A1
Antinori, A; Canovari, B; Colafigli, M; Colangeli, V; D'Arminio Monforte, A; D'Avino, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Fantauzzi, A; Francisci, D; Gagliardini, R; Ghisetti, V; Grima, P; Lamonica, S; Latini, A; Lisi, L; Mastroianni, C; Meini, G; Micheli, V; Navarra, P; Orofino, G; Re, MC; Rossetti, B; Rusconi, S; Sterrantino, G; Trezzi, M; Vignale, F; Vullo, V; Zazzi, M1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Molina, JM; Nguyen, BY; Rodgers, A; Sax, PE; Sklar, P; Squires, K; Xu, X1
Anderson, MS; Fan, L; Iwamoto, M; Khalilieh, SG; Laethem, T; Rasmussen, S; Sanchez, RI; Sura, M; van Bortel, L; van Lancker, G; Yee, KL1
Bickel, M; Cahn, P; Greaves, W; Hanna, GJ; Hwang, C; Johnson, M; Kumar, P; Kumar, S; Mallolas, J; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Zhou, Y1
Cahn, P; DeJesus, E; Hanna, GJ; Hwang, C; Kumar, S; Lai, MT; Lombaard, J; Lupinacci, L; Martin, EA; Molina, JM; Rodgers, A; Sax, PE; Sklar, P; Squires, K1
Appeltans, B; Pas, T; Van den Mooter, G; Verbert, S1
Alvarez Bognar, F; Elion, R; Hwang, C; Martin, EA; Orkin, C; Rockstroh, JK; Sklar, P; Thompson, M; Xu, ZJ1

Reviews

1 review(s) available for triazoles and ritonavir

ArticleYear
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
    Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole

2014

Trials

17 trial(s) available for triazoles and ritonavir

ArticleYear
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Clinical pharmacology and therapeutics, 2006, Volume: 80, Issue:2

    Topics: Adult; Alleles; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Genotype; Humans; Male; Mixed Function Oxygenases; Pyrimidines; Ritonavir; Triazoles; Voriconazole

2006
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10

    Topics: Adult; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Drug Interactions; Humans; Male; Middle Aged; Pyrimidines; Ritonavir; Sample Size; Triazoles; Voriconazole

2007
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
    Journal of acquired immune deficiency syndromes (1999), 2009, Aug-01, Volume: 51, Issue:4

    Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Benzoxazines; Cross-Over Studies; Cyclopropanes; Drug Interactions; Female; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Triazoles

2009
Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
    Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Cyclohexanes; Drug Interactions; Drug Therapy, Combination; Half-Life; Humans; Maraviroc; Quinolones; Ritonavir; Triazoles; Young Adult

2010
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Journal of acquired immune deficiency syndromes (1999), 2010, Dec-15, Volume: 55, Issue:5

    Topics: Adult; Albumins; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System Infections; Cross-Over Studies; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immunoglobulin G; Lopinavir; Male; Maraviroc; Middle Aged; Neopterin; Peptide Fragments; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Triazoles; Viral Load; Viremia; Virus Replication

2010
Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5

    Topics: Adolescent; Adult; Cyclohexanes; Darunavir; Drug Interactions; Female; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Young Adult

2011
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
    Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:5

    Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Midazolam; Middle Aged; Pyrimidines; Ritonavir; Time Factors; Triazoles; Voriconazole; Young Adult

2011
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult

2013
Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Cyclohexanes; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Furans; Humans; Male; Maraviroc; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Triazoles

2013
Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; DNA, Viral; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Maraviroc; Prospective Studies; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2015
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:7

    Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Piperazines; Ritonavir; Triazoles; Young Adult

2015
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 R
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016, 07-01, Volume: 63, Issue:1

    Topics: Adult; Comorbidity; Cyclohexanes; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Triazoles; Viral Load; Virus Replication

2016
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
    The Journal of antimicrobial chemotherapy, 2017, 06-01, Volume: 72, Issue:6

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Maraviroc; Medication Adherence; Post-Exposure Prophylaxis; Ritonavir; Triazoles; Young Adult

2017
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2017
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    The lancet. HIV, 2018, Volume: 5, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load

2018
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
    Journal of acquired immune deficiency syndromes (1999), 2019, 08-01, Volume: 81, Issue:4

    Topics: Adult; Aged; Anti-Retroviral Agents; Equivalence Trials as Topic; Female; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; Pyridones; Quinolones; Ritonavir; Tenofovir; Treatment Outcome; Triazoles; Young Adult

2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
    The lancet. HIV, 2020, Volume: 7, Issue:1

    Topics: Adult; Anti-HIV Agents; Darunavir; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult

2020

Other Studies

20 other study(ies) available for triazoles and ritonavir

ArticleYear
Maraviroc: in vitro assessment of drug-drug interaction potential.
    British journal of clinical pharmacology, 2008, Volume: 66, Issue:4

    Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles

2008
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.
    Medical mycology, 2010, Volume: 48, Issue:3

    Topics: Anti-HIV Agents; Antifungal Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Monitoring; HIV Infections; Humans; Interferon-gamma; Lamivudine; Male; Meningitis, Cryptococcal; Pyrimidines; Ritonavir; Serum; Triazoles; Voriconazole; Young Adult

2010
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
    AIDS (London, England), 2011, Feb-20, Volume: 25, Issue:4

    Topics: Anti-Retroviral Agents; Aspergillosis; Aspergillus; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles; Voriconazole

2011
Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:3

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Darunavir; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; Sulfonamides; Triazoles

2012
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.
    AIDS (London, England), 2012, Mar-27, Volume: 26, Issue:6

    Topics: Aspergillosis; Female; HIV Infections; Humans; Male; Pneumonia, Aspiration; Pyridazines; Pyrimidines; Ritonavir; Triazoles

2012
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
    PLoS pathogens, 2012, Volume: 8, Issue:6

    Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia

2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
    AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14

    Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load

2012
Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
    The Journal of antimicrobial chemotherapy, 2012, Volume: 67, Issue:11

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Drug Interactions; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Nitriles; Plasma; Pyridazines; Pyrimidines; Ritonavir; Triazoles

2012
Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; Half-Life; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles

2013
Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:7

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Plasma; Ritonavir; Time Factors; Triazoles

2013
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
    Circulation, 2013, May-28, Volume: 127, Issue:21

    Topics: Animals; Anti-Retroviral Agents; Apolipoproteins E; Atherosclerosis; CCR5 Receptor Antagonists; Cell Movement; Chemokine CCL2; Chemokine CCL5; Cyclohexanes; Disease Models, Animal; Intercellular Adhesion Molecule-1; Interleukin-17; Macrophages; Male; Maraviroc; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Ritonavir; Treatment Outcome; Triazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1

2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Journal of acquired immune deficiency syndromes (1999), 2013, Oct-01, Volume: 64, Issue:2

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Pilot Projects; Ritonavir; RNA Stability; RNA, Viral; Sulfonamides; Treatment Outcome; Triazoles; Viral Load

2013
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    HIV medicine, 2014, Volume: 15, Issue:7

    Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Triazoles

2014
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:9

    Topics: Adult; Anti-HIV Agents; Cyclohexanes; HIV Infections; Humans; Lopinavir; Male; Maraviroc; Middle Aged; Plasma; Ritonavir; Semen; Triazoles

2014
Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; Dideoxynucleosides; Feasibility Studies; Female; Humans; Male; Maraviroc; Middle Aged; Organophosphonates; Ritonavir; Tenofovir; Triazoles

2014
Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
    AIDS research and human retroviruses, 2014, Volume: 30, Issue:12

    Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemokine CCL5; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Envelope Protein gp120; HIV Reverse Transcriptase; HIV-1; Humans; Maraviroc; Oxazines; Peptide Fragments; Phylogeny; Piperazines; Pyridones; Receptors, CCR5; Receptors, CXCR4; Ritonavir; Sulfonamides; Triazoles; Viral Load; Viral Tropism

2014
Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
    International journal of STD & AIDS, 2016, Volume: 27, Issue:4

    Topics: Adult; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Darunavir; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Nervous System; Ritonavir; RNA, Viral; Treatment Outcome; Triazoles; Viral Load

2016
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyridones; Ritonavir; Triazoles; Young Adult

2019
The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
    International journal of pharmaceutics, 2020, Jan-05, Volume: 573

    Topics: Administration, Oral; Antifungal Agents; Antiviral Agents; Biological Availability; Chemistry, Pharmaceutical; Crystallization; Drug Compounding; Drug Liberation; Equivalence Trials as Topic; Itraconazole; Nitriles; Particle Size; Pyridazines; Pyrimidines; Research Design; Ritonavir; Solubility; Therapeutic Equivalency; Triazoles; X-Ray Diffraction

2020
Changes in weight and BMI with first-line doravirine-based therapy.
    AIDS (London, England), 2021, 01-01, Volume: 35, Issue:1

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; CD4 Lymphocyte Count; Darunavir; HIV Infections; Humans; Pyridones; Ritonavir; Treatment Outcome; Triazoles; Viral Load

2021